Xilio Therapeutics, Inc. (XLO)
USD 0.87
(-6.56%)
USD 0.87
(-6.56%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -68.62 Thousand | -75.72 Million | -80.75 Million | -36.09 Million | -17.84 Million |
| Net Income | -76.4 Thousand | -88.22 Million | -75.8 Million | -55.21 Million | -17.31 Million |
| Depreciation & Amortization | 1900.00 | 1.84 Million | 1.49 Million | 1.06 Million | 240 Thousand |
| Deferred income taxes | 2.06 Million | - | 222 Thousand | 126 Thousand | -1.73 Million |
| Stock-based compensation | 7382.00 | 8.42 Million | 4.95 Million | 1.29 Million | 112 Thousand |
| Change in working capital | 405.00 | 2 Million | -11.8 Million | 16.6 Million | 797 Thousand |
| Other non-cash items | -1903.00 | 224 Thousand | 173 Thousand | 39 Thousand | 56 Thousand |
| Investing Cash Flow | -486.00 | -1.86 Million | -1.1 Million | -2.18 Million | -715 Thousand |
| Investments in PPE | -486.00 | -1.86 Million | -1.1 Million | -2.18 Million | -715 Thousand |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | -6550.00 | -69 Thousand | 260.66 Million | 10.02 Million | 60.02 Million |
| Debt repayment | -6752.00 | -85 Thousand | -1.08 Million | -99 Thousand | -190 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | 194 Thousand | - | - | - | - |
| Common Stock Issuance | 202 Thousand | 16 Thousand | 116.35 Million | 10.12 Million | 60.02 Million |
| Other Financing Activities | 202.00 | -69.00 | 145.39 Million | 10.02 Thousand | 190 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -2.06 Million | 485 Thousand | -2.81 Million | 2.92 Million | 970 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | 405.00 | 1.51 Million | -8.98 Million | 13.67 Million | -173 Thousand |
| Cash at beginning of period | 121.94 Thousand | 199.6 Million | 20.78 Million | 49.03 Million | 7.57 Million |
| Cash at end of period | 46.29 Thousand | 121.94 Million | 199.6 Million | 20.78 Million | 49.03 Million |
| Capital Expenditure | -486.00 | -1.86 Million | -1.1 Million | -2.18 Million | -715 Thousand |
| Effect of forex changes on cash | -25 Thousand | - | - | - | - |
| Net cash flow / Change in cash | -75.65 Thousand | -77.65 Million | 178.81 Million | -28.25 Million | 41.46 Million |
| Free Cash Flow | -69.1 Thousand | -77.59 Million | -81.85 Million | -38.27 Million | -18.55 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -13.92 Million | -17.2 Million | -76.4 Million | -17.65 Million | -16.74 Million | -19.35 Million |
| Depreciation & Amortization | 445 Thousand | 443 Thousand | 1.9 Million | 449 Thousand | 460 Thousand | 492 Thousand |
| Deferred income taxes | - | - | 2.06 Million | -1.33 Million | 1000.00 | 2000.00 |
| Stock-based compensation | 1.51 Million | 1.83 Million | 7382.00 | 1930.00 | 1.86 Million | 1.8 Million |
| Change in working capital | 31.92 Million | 4.42 Million | -1.65 Million | 1.83 Million | 1.03 Million | 400 Thousand |
| Other non-cash items | 1.89 Million | 33.02 Million | 13.4 Million | 3.28 Million | 23 Thousand | 87 Thousand |
| Investing Cash Flow | -21 Thousand | - | -486 Thousand | - | - | -316 Thousand |
| Investments in PPE | -21 Thousand | - | -486 Thousand | - | - | -316 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 20.04 Million | 954 Thousand | -6.55 Million | -1.63 Million | -2236.00 | -992.00 |
| Debt repayment | -21 Thousand | -3.35 Million | -6.75 Million | -1.68 Million | -2244.00 | -1132.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 4.3 Million | 194 Thousand | 194 Thousand | - | - |
| Common Stock Issuance | 20.06 Million | 4.3 Million | 202 Thousand | 54 Thousand | 8000.00 | 140 Thousand |
| Other Financing Activities | 17.54 Million | 4308.00 | 202.00 | 54.00 | 8.00 | 140.00 |
| Accounts receivables | - | -30 Million | - | - | - | - |
| Accounts payables | 509 Thousand | -304 Thousand | -2.06 Million | -438 Thousand | 542 Thousand | -809 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.41 Million | 34.73 Million | 405 Thousand | 2.27 Million | 492 Thousand | 1.2 Million |
| Cash at beginning of period | 33.98 Million | 44.7 Million | 120.38 Million | 59.77 Million | 76.95 Million | 94.83 Million |
| Cash at end of period | 74.94 Million | 33.98 Million | 44.7 Million | 44.7 Million | 61.35 Million | 76.95 Million |
| Capital Expenditure | -21 Thousand | - | -486 Thousand | - | - | -316 Thousand |
| Effect of forex changes on cash | - | - | -25 Thousand | -23.19 Million | - | 23.19 Million |
| Net cash flow / Change in cash | 40.96 Million | -10.72 Million | -75.68 Million | -15.06 Million | -15.6 Million | -17.88 Million |
| Free Cash Flow | 19.93 Million | -10.5 Million | -69.1 Million | -13.42 Million | -13.36 Million | -16.89 Million |
SAVA
600368
6093
EMMN
603797
RAMANEWS